Studying Depression at a Molecular Level

Michal Slezak, PhD

A recent study suggests that alterations in astrocyte metabolism is a major hallmark of depression. In this Mental Health Minute, Michal Slezak, PhD, explains how he and other researchers used state-of-the-art imaging techniques and genetic approaches to identify molecular processes impaired in depression. The researchers propose that novel, glial-specific drugs could target the molecular mechanics of depression.

Dr Slezak is a group leader at BioMed X Institute studying brain microcircuits in psychiatric diseases.

Does addressing depression at the molecular level sound like a promising treatment to you? Share comments with your colleagues by emailing PTEditor@mmhgroup.com. Comments may be shared online pending review and editing for style.